<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890470</url>
  </required_header>
  <id_info>
    <org_study_id>UESTC-neuSCAN-78</org_study_id>
    <nct_id>NCT04890470</nct_id>
  </id_info>
  <brief_title>Effects of Oxytocin and Vasopressin on Moral Decision Making</brief_title>
  <official_title>Effects of Oxytocin and Vasopressin on Moral Decision Making</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Electronic Science and Technology of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Electronic Science and Technology of China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether the neuropeptide oxytocin (OXT) and vassopressin (AVP) influence moral&#xD;
      decision making&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a double-blind, between- subject placebo (PLC) controlled design, subjects will first&#xD;
      complete a serious of questionnaires in terms of mood, clinical symptoms, and traits. After&#xD;
      that their moral judgment and emotion towards both verbal descriptions of moral dilemma&#xD;
      scenarios and pictures of specific interpersonal ones will be assessed and the effect of&#xD;
      intranasal OXT and AVP between both male and female healthy subjects will be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of OXT and AVP on behavioral index of moral decision task</measure>
    <time_frame>45 mins - 105 mins</time_frame>
    <description>intensity of feelings</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>oxytocin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with oxytocin treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vasopressin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with vasopressin treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects with placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>intranasal administration of oxytocin (24 IU)</description>
    <arm_group_label>oxytocin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>intranasal administration of vasopressin (20 IU)</description>
    <arm_group_label>vasopressin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intranasal administration of placebo</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy subjects without past or current psychiatric or neurological disorders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith M. Kendrick</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Electronic Science and Technology of China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keith M. Kendrick, Dr.</last_name>
    <phone>86-28-61830811</phone>
    <email>k.kendrick.uestc@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benjamin Becker, Dr.</last_name>
    <phone>86-28-61830988</phone>
    <email>ben_becker@gmx.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xiaoxiao Zheng</name>
      <address>
        <city>Sichuan</city>
        <state>Sichuan</state>
        <zip>611731</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoxiao Zheng, Dr.</last_name>
      <phone>86-18224488432</phone>
      <email>zhengxx003@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Qin Li, Dr.</last_name>
      <phone>86-28-61830811</phone>
      <email>helenlee@uestc.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 16, 2021</last_update_submitted>
  <last_update_submitted_qc>May 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Electronic Science and Technology of China</investigator_affiliation>
    <investigator_full_name>Keith Kendrick</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>moral decision making</keyword>
  <keyword>oxytocin</keyword>
  <keyword>vasopressin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

